Mirvie

Mirvie is a private, pre-revenue diagnostics company pioneering a predictive RNA platform for pregnancy complications. Its core technology uses machine learning to analyze cell-free RNA signals from the mother, placenta, and fetus, enabling early risk assessment for conditions like preeclampsia. The company's lead product, the Encompass Test for preeclampsia prediction, has garnered recognition and is supported by landmark peer-reviewed research. Mirvie aims to address the significant unmet need in maternal-fetal health, where one in five pregnancies is affected by complications.

Proprietary RNA platform analyzing tens of thousands of cell-free RNA messages from maternal blood (from mother, placenta, and fetus) combined with machine learning to predict pregnancy complications months in advance.

Mirvie appears to be a first-mover in commercializing a cfRNA-based predictive platform for multiple pregnancy complications. Competition exists from companies focusing on single biomarkers or proteins for preeclampsia risk (e.g., Thermo Fisher's PlGF test) and from academic groups researching multi-omic signatures, but Mirvie's integrated platform and published research provide a competitive edge.